Piper Jaffray analyst Tyler Van Buren says he is "not shocked at all" by Gilead's STELLAR3 whiff given the prior failure of STELLAR4. With that said, the fact that placebo outperformed selonsertib was particularly unfortunate and suggests that the compound is all but dead, unless the company can revive it via combination strategies, he contends. The analyst believes this further emphasizes the fact that Gilead's pipeline "does not pack enough punch" for a company of its size. Van Burren reiterates a Neutral rating and a $75 price target on the shares.